Clinical trials: Choroidal Disease
Neovascular Age-related Macular Degeneration
Long-term Results After Intravitreal Bevacizumab Treatment Of Neovascular Age-related Macular Degeneration
200 eyes with each subtype of neovascular age-related macular degeneration will be included in this study and 3 years after the initial intravitreal bevacizumab, best-corrected visual acuity (BCVA) will be measured using Snellen…
- Trial name
- NCT01027468
- Testing
- Bevacizumab
- Volunteers
- 160 people
- Sponsor
- Medical University of Vienna
Choroidal Melanoma, Indeterminate Lesions
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma
AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial.
- Trial name
- CoMpass (NCT07338968)
- Testing
- Observational
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- Aura Biosciences
Macular Degeneration
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary…
- Trial name
- NCT00090623
- Testing
- rhuFab V2 (ranibizumab)
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Genentech, Inc.
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Epiretinal Membrane
Choroidal Thickness Vitrectomy
The purpose of this study is to assess the influence of vitrectomy on changes in central choroidea and comparing the results in imaging of the choroidea with two different OCT devices.
- Trial name
- NCT02617147
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Medical University of Vienna
Age-related Macular Degeneration
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
This was a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with neovascular age related macular degeneration (nAMD) who have not previously received anti- vascular endothelial growth…
- Trial name
- TALON (NCT04005352)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 734 people
- Sponsor
- Novartis Pharmaceuticals
Choroid
Three-dimensional Choroidal Vascularity Index in Common Fundus Diseases
Explore the changes of choroidal blood perfusion in common fundus diseases by three-dimensional choroidal vascularity index, an optical coherence tomography (OCT) parameter.
- Trial name
- NCT04790084
- Testing
- no intervention
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Macular Polypoidal Choroidal Vasculopathy (PCV)
Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy
This study is a 60-week, two-arm, randomized, open-label, active-controlled, multi-center study in patients with Polypoidal choroidal vasculopathy (PCV) who have not previously received anti-Vascular endothelial growth factor…
- Trial name
- PROUD (NCT05666804)
- Testing
- Brolucizumab 6mg
- Where
- 15 sites in South Korea
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Polypoidal Choroidal Vasculopathy
OCTA and Polypoidal Choroidal Vasculopathy
To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.
- Trial name
- NCT04714242
- Testing
- Ranibizumab Injection
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Federico II University
Coronary Vasospasm
Effect of Glucose on Ocular Blood Flow
The primary objective is to assess the effect of glucose on retinal vascular diameter in otherwise healthy vasospastic subjects compared to non-vasospastic controls.
- Trial name
- NCT00350129
- Where
- Switzerland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Age-Related Maculopathy, Choroidal Neovascularization
Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration
In this pilot study the researchers will evaluate the safety and efficacy of 50% reduced fluence PDT combination therapy with ranibizumab.
- Trial name
- NCT00473642
- Testing
- Ranibizumab, Verteporfin
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Oklahoma State University Center for Health Sciences
Uveal Melanoma
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
- Trial name
- NCT07804186
- Testing
- Darovasertib, Crizotinib (Xalkori)
- Where
- 13 sites in United States, Canada
- Volunteers
- 450 people
- Sponsor
- IDEAYA Biosciences
Polypoidal Chorodial Vasculopathy, Age Related Macular Degeneration
IRay to Treat Polypoidal Choroidal Vasculopathy (PCV) Secondary to Age-Related Macular Degeneration (AMD
This study will evaluate the efficacy of IRay treatment in patients with Polypoidal Choroidal Vasculopathy (PCV)secondary to AMD as determined by the change in the proportion of lesion activity and lesion size at 12 months.
- Trial name
- NCT01516294
- Testing
- Iray
- Where
- Italy
- Volunteers
- 12 people
- Sponsor
- Oraya Therapeutics, Inc.
Tuberculosis (TB), Uveitis
Six-months Versus Nine-months ATT for Ocular TB
The goal of this clinical trial is to learn if 6-months anti-TB therapy is not worse than 9-months therapy for the treatment of tubercular posterior uveitis.
- Conditions
- Tuberculosis (TB), Uveitis, Retinal Vasculitis, Choroiditis
- Trial name
- NCT06613919
- Testing
- Anti-Tuberculosis Treatment
- Where
- 3 sites in Burma, India and 1 more
- Volunteers
- 58 people
- Sponsor
- L.V. Prasad Eye Institute
Choroideremia
Gene Therapy for Blindness Caused by Choroideremia
Primary objective: To assess the safety and tolerability of the AAV.REP1 vector, administered at two different doses to the retina in 12 patients with a diagnosis of choroideremia.
- Trial name
- NCT01461213
- Testing
- rAAV2.REP1
- Where
- 4 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- University of Oxford
Choroidal Neovascularization, Age Related Macular Degeneration
Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD
The purpose of the study is to detect persisting or early new activity of choroidal neovascularization (CNV) due to age related macular degeneration (AMD) during the first 12 months following the first ranibizumab dose at…
- Trial name
- NCT03393767
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- Vista Klinik
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Glaucoma
Evaluate the Safety and Effectiveness of iSTAR Medical's MINIject™ Implant for Lowering Intraocular Pressure (IOP) in Subjects With Primary Open-angle Glaucoma.
Evaluate the safety and effectiveness of iSTAR Medical's MINIject™ implant for lowering intraocular pressure (IOP) in subjects with primary open-angle glaucoma.
- Trial name
- STAR-V (NCT05024695)
- Testing
- MINIject™ Implant
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 975 people
- Sponsor
- iSTAR Medical
Uveal Melanoma, Ocular Melanoma
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
The primary objective is to determine the safety, tolerability, and preliminary efficacy of belzupacap sarotalocan for the treatment of primary indeterminate lesions and small choroidal melanoma (IL/CM).
- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Trial name
- NCT04417530
- Testing
- AU-011, Suprachoroidal Microinjector, PDT Laser
- Where
- 22 sites in United States
- Volunteers
- 22 people
- Sponsor
- Aura Biosciences
Ocular Surface Disease, Inflammatory Disease
Establishment of a Multimodal Standard Database for Inflammation-related Ophthalmopathy
Through a systematic observational study, the intrinsic connections and patterns between the occurrence and development of common blinding retinal diseases such as diabetic retinopathy, pathological myopia, and age-related…
- Conditions
- Ocular Surface Disease, Inflammatory Disease, Retinal Disease, Choroid Diseases
- Trial name
- NCT07628946
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Dan Chen